Medical News

Resistance in Enterobacterales is Higher Among People with H...
Clin Infect Dis

In a large clinical study population in the southeastern US from 2000-2018, the prevalence of antibacterial...

14 Oct 2021

A Retrospective Study of Survival and Risk Factors for Morta...
AIDS Res. Ther.

This study demonstrated the substantial mortality rate over the consecutive 5 years of the follow-up period among...

13 Oct 2021

Alcohol, Smoking, Recreational Drug Use and Association with...
HIV Med

Screening and treatment for alcohol, cigarette and drug use should be integrated into HIV outpatient clinics, while...

12 Oct 2021

Sex Differences in HIV Persistence and Reservoir Size during...
Clin Infect Dis

In contrast to men, where the HIV reservoir steadily declines with aging, the HIV reservoir in women is more...

07 Oct 2021

Key Trials

Daily PrEP Verses on Demand PrEP Regimen Coverage CLAI for MSM

The present study determined the impacts of oral tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF/FTC) on demand verses daily PrEP   ...

BRAAVE Trial: Efficacy of Switching to STR of B/F/TAF vs Continuing on Regimen of 2 NRTIs and a Third Agent in Virologically Suppressed HIV Adults

BRAAVE study is the randomized phase 3 study evaluating efficacy and safety of   switching to fixed-dose combination of B/F/TAF vs continuing...

Safety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in People with HIV

The present study evaluated safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine in people with HIV (PLHIV) in a well characterised UK cohort....

AMBER and EMERALD Trial: 96-week Resistance Analysis of Once-daily Single Tablet Regimen of D/C/F/TAF in HIV-1 Adults Patients

The present study is a 96-week resistance analysis of AMBER and EMERALD trials, evaluating efficacy and safety of darunavir/cobicistat/emtricitabine...

Our Publications

Antiretroviral-based Prevention Strategies in HIV

Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...

Antiretroviral Therapy – Current Recommendations

Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....

Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets

Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...

Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets

Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...

Patient Education

Live Healthier, Live Longer

This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment....

Living with Hope

This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects. ...

Slide Library

HIV - HCV Coinfection

This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...

 
Email this page
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use

PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...

 
Email this page
HIV- Post-exposure Prophylaxis (PEP)

Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...

 
Email this page
Isoniazid Preventive Therapy in HIV Infection

HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....

 
Email this page

Infographics

Explore >>

Currently there is no content under this category.

Poll

Which is your preferred 3rd drug in a first-line regimen?

Efavirenz 600
50% (3 votes)
Efavirenz 400
17% (1 vote)
Dolutegravir
33% (2 votes)
Total votes: 6